Finance

Lists
CONCORDBIO:NSE
Concord Biotech Ltd
1 341,50 INR
-0,87%
(-11,80) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for CONCORDBIO...
Open
1 362,90 INR
High
1 366,80 INR
Low
1 332,00 INR
Mkt. cap
140,34 მლრ.
Avg. vol.
131,96 ათ.
Volume
45,38 ათ.
Dividend
0,56%
Quarterly dividend
1,89 INR
Ex-dividend date
24 ივლ. 2026
P/E ratio
50,99
52-wk high
1 615,00 INR
52-wk low
987,00 INR
EPS
26,31 INR
No. of employees
2 ათ.
Open
1 362,90 INR
High
1 366,80 INR
Low
1 332,00 INR
Mkt. cap
140,34 მლრ.
Avg. vol.
131,96 ათ.
Volume
45,38 ათ.
Dividend
0,56%
Quarterly dividend
1,89 INR
Ex-dividend date
24 ივლ. 2026
P/E ratio
50,99
52-wk high
1 615,00 INR
52-wk low
987,00 INR
EPS
26,31 INR
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients sold worldwide. It manufactures biopharmaceutical products across therapy segments such as immunosuppressant, oncology, antifungal, antibacterial and anthelmintic. It has two manufacturing facilities–at Dholka near Ahmedabad, which is approved by USFDA, and at Limbasi in Kheda district. Wikipedia
About Concord Biotech Ltd
CEO-
Employees1,62 ათ.
Founded2000
Headquarters-
SectorPharmaceutical industry
Last report
3 აგვ. 2026
Fiscal period
Q1 2027
5,52 INR / 5,60 INR
-1,43%miss
Revenue / Est. (INR)
2,57 მლრდ. / 2,45 მლრდ.
+5,05%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
2,47 მლრდ.
2,78 მლრდ.
3,26 მლრდ.
2,57 მლრდ.
Cost of goods sold
775,44 მლნ.
941,71 მლნ.
1,32 მლრდ.
890,11 მლნ.
Cost of revenue
775,44 მლნ.
941,71 მლნ.
1,32 მლრდ.
890,11 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
444,56 მლნ.
467,81 მლნ.
477,71 მლნ.
436,38 მლნ.
Operating expense
994,14 მლნ.
1,03 მლრდ.
837,11 მლნ.
1,04 მლრდ.
Total operating expenses
1,77 მლრდ.
1,98 მლრდ.
2,16 მლრდ.
1,93 მლრდ.
Operating income
701,00 მლნ.
802,34 მლნ.
1,10 მლრდ.
642,76 მლნ.
Other non operating income
133,52 მლნ.
99,76 მლნ.
-356,29 მლნ.
128,26 მლნ.
EBT including unusual items
856,84 მლნ.
861,56 მლნ.
1,14 მლრდ.
783,43 მლნ.
EBT excluding unusual items
856,84 მლნ.
894,31 მლნ.
929,35 მლნ.
783,43 მლნ.
Income tax expense
226,21 მლნ.
225,14 მლნ.
256,08 მლნ.
206,46 მლნ.
Effective tax rate
26,40%
26,13%
22,45%
26,35%
Other operating expenses
365,67 მლნ.
378,34 მლნ.
163,96 მლნ.
424,64 მლნ.
Net income
635,81 მლნ.
644,77 მლნ.
887,90 მლნ.
585,26 მლნ.
Net profit margin
25,74%
23,21%
27,23%
22,73%
Earnings per share
6,03
6,31
8,46
5,52
Interest and investment income
-
-
24,63 მლნ.
-
Interest expense
-591,00 ათ.
-815,00 ათ.
-840,00 ათ.
-364,00 ათ.
Net interest expenses
-591,00 ათ.
-815,00 ათ.
23,79 მლნ.
-364,00 ათ.
Depreciation and amortization charges
183,92 მლნ.
187,47 მლნ.
195,44 მლნ.
181,00 მლნ.
EBITDA
881,84 მლნ.
933,85 მლნ.
1,28 მლრდ.
824,23 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები